The ADRC is currently recruiting participants for:

    Connect Study

    Description: This study will determine the safety and efficacy of the experimental drug AZD0530 (saracatinib) in older adults with mild Alzheimer's disease. Researchers want to know if the drug can slow disease progression by inhibiting the protein Fyn kinase. AZD0530 was previously developed as a cancer therapy.

    Study Length: 52 Weeks

    Study Requirements
    • 55-85 years of age
    • Individuals with a diagnosis of mild to moderate Alzheimer's disease
    • A study partner who will accompany the participant to all clinic visit
    Contact:
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    Biogen (Emerge-Engage) Study

    Description: This study will evaluate the efficacy and safety of an investigational drug, Aducanumab, for individuals with Early, Mild Alzheimer's Disease or certain types of Mild Cognitive Impairment (MCI). Study medication is administered by a once monthly infusion.

    Study Length: 18 months

    Study Requirements
    • 50-85 years of age
    • Diagnosis of mild Alzheimer's disease or certain types of MCI
    • A study partner who will accompany the participant to all clinic visits
    Contact:
    Carolyn Rickard at 412-692-2707 or mishlercj@upmc.edu or
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    STARBEAM Study (Lundbeck)

    Description: The primary objective of this study is to establish the efficacy of an investigational medication (Lu AE58054) as adjunctive therapy to Donepezil for symptomatic treatment of patients with mild-moderate Alzheimer's disease.

    Study Length: 7 months

    Study Requirements
    • Individuals age 50 or older with mild-moderate Alzheimer's disease
    • Not currently taking memantine
    • Stable treatment with donepezil
    • A study partner who will accompany the participant to all clinic visits
    Contact:
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
    AMBAR Study

    Description: The purpose of this study is to determine whether short-term followed by long-term, low-volume plasma exchange (a process of blood filtering) is able to modify Alzheimer Disease patient's cognitive, functional, and behavioral symptoms.

    Study Length: 14 months (Six weekly plasmapheresis sessions followed by 12 monthly plasmapheresis sessions)

    Study Requirements
    • 55-85 years of age
    • Individuals with a diagnosis of mild to moderate Alzheimer's disease
    • A study partner who will accompany the participant to all clinic visits
    Contact:
    Donna Simpson, 412-692-2717 or simpsondm@upmc.edu or
    MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu


The University of Pittsburgh Alzheimer Disease Research Center (ADRC) is one of the nation's leading research centers specializing in the diagnosis of Alzheimer's disease and related disorders. Through outpatient evaluations, participants and their families receive state-of-the-art diagnostic assessments and contribute to the scientific study of Alzheimer's disease

Learn More »

Our memory evaluation is an extensive diagnostic evaluation of individuals with suspected Alzheimer's disease and other types of memory loss and/or cognitive impairment. The professionals at the ADRC understand that this is a stressful process for all and assure that individuals will be treated with sensitivity and respect.

Learn More »

Top